US pregnancy guidelines updated (Dec 2005)
The Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States have been revised to include:
- Updates to Clinical Scenario #3. The new information discusses a 3 to 7 day tail of postpartum maternal ZDV/3TC following single dose maternal/infant nevirapine; this tail may reduce the risk of nevirapine resistance.
- Updated information on the role of cesarean delivery in preventing mother-to-child transmission of HIV.
- An updated Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy, including a new section on tipranavir.
- A Perinatal Antiretroviral Guidelines Working Group Conflict of Interest Disclosure (Appendix).
Updated information appears highlighted in yellow.
You can download the updated guidelines, or request to receive them by e-mail or hard copy from the AIDSinfo Web site:
AIDSinfo – HIV / Medical Practice Guidelines
The AIDSinfo website is also a useful source of other information related to HIV/AIDS, including other treatment and prevention guidelines, downloadable databases for PDAs (Personal Digital Assistants), fact sheets, and HIV/AIDS-related clinical trials information.
Source: FDA list serve